Storia in 2 fonti

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales.

Raccontata da

cnbc.com

biopharmadive.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo3 mesi fa

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales.

originale

biopharmadive.com3 mesi fa

Novo hikes guidance on Wegovy pill’s fast sales start

In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pill.

Leggi questa versione → originale

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Confronto fonti

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Novo hikes guidance on Wegovy pill’s fast sales start

Timeline cronologica

Wegovy pill sales smash forecasts after launch as Novo Nordisk hikes guidance

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Novo hikes guidance on Wegovy pill’s fast sales start